MarketCap
Facebook
X
TelegramAnnual report 2025
added 04-25-2026
Adagene Operating Cash Flow 2011-2026 | ADAG
Annual Operating Cash Flow Adagene
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -15.7 M | -29.7 M | -28.5 M | -48.6 M | -43.4 M | -28.5 M | -18.2 M | -14.3 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -14.3 M | -48.6 M | -28.3 M |
Operating Cash Flow of other stocks in the Biotechnology industry
| Issuer | Operating Cash Flow | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-481 M | - | 2.43 % | $ 254 M |  Germany |
 |
Amphastar Pharmaceuticals
AMPH
|
156 M | $ 21.77 | 1.68 % | $ 1.02 B |  USA |
 |
I-Mab
IMAB
|
-1.3 B | - | - | $ 866 M |  China |
 |
Aeglea BioTherapeutics
AGLE
|
-169 M | - | - | $ 1.01 B | USA |
 |
Midatech Pharma plc
MTP
|
-6.01 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Aptorum Group Limited
APM
|
-1.84 M | $ 0.92 | 3.05 % | $ 6.76 M | China |
 |
Biophytis SA
BPTS
|
-23.8 M | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
99.9 M | - | 2.54 % | $ 160 B | France |
 |
ACADIA Pharmaceuticals
ACAD
|
158 M | $ 22.44 | 2.16 % | $ 3.72 B | USA |
 |
Esperion Therapeutics
ESPR
|
-13.1 M | $ 2.02 | 5.76 % | $ 420 M | USA |
 |
Advaxis
ADXS
|
-29.5 M | - | -9.65 % | $ 45.9 M | USA |
 |
AIkido Pharma
AIKI
|
22.7 M | - | 1.93 % | $ 17.4 M | USA |
 |
Galectin Therapeutics
GALT
|
-23.9 M | $ 2.42 | 3.65 % | $ 155 M | USA |
 |
Akouos
AKUS
|
-63.7 M | - | 0.23 % | $ 488 M | USA |
 |
Allakos
ALLK
|
-116 M | - | - | $ 28.6 M | USA |
 |
AlloVir
ALVR
|
-38.4 M | - | 4.14 % | $ 49.1 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-8.56 M | - | -11.43 % | $ 502 K | USA |
 |
Heron Therapeutics
HRTX
|
-27.6 M | $ 1.26 | 6.3 % | $ 210 M | USA |
 |
Applied Molecular Transport
AMTI
|
-93.9 M | - | - | $ 10.1 M | USA |
 |
ImmuCell Corporation
ICCC
|
2.48 M | $ 8.28 | -0.84 % | $ 74.7 M | USA |
 |
Aeterna Zentaris
AEZS
|
-8.58 M | - | 5.93 % | $ 314 M |  Canada |
 |
Brainstorm Cell Therapeutics
BCLI
|
-6.98 M | - | -2.5 % | $ 5.88 M | USA |
 |
Applied Therapeutics
APLT
|
-55.2 M | - | - | $ 8.42 M | USA |
 |
Aptinyx
APTX
|
-59.7 M | - | -39.0 % | $ 4.57 M | USA |
 |
AgeX Therapeutics
AGE
|
-18 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aravive
ARAV
|
-65.1 M | - | -13.39 % | $ 1.45 M | USA |
 |
InflaRx N.V.
IFRX
|
-39.9 M | $ 1.53 | 3.38 % | $ 152 M | Germany |
 |
Aridis Pharmaceuticals
ARDS
|
-29.1 M | - | 17.91 % | $ 11.1 M | USA |
 |
BioNTech SE
BNTX
|
890 M | $ 103.31 | -2.04 % | $ 27.2 B | Germany |
 |
Avenue Therapeutics
ATXI
|
-1.83 M | - | -52.27 % | $ 4.45 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-65.7 M | - | - | $ 26.5 M | USA |
 |
Aquestive Therapeutics
AQST
|
-52.4 M | $ 4.14 | 1.47 % | $ 443 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
-5.62 M | $ 23.57 | 1.33 % | $ 3 B | USA |
 |
Innate Pharma S.A.
IPHA
|
-58.5 M | $ 1.39 | 0.72 % | $ 235 M | France |
 |
Inventiva S.A.
IVA
|
-47.6 M | $ 5.18 | 0.49 % | $ 138 M | France |
 |
Jaguar Health
JAGX
|
-23.7 M | $ 0.36 | -8.39 % | $ 840 K | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-34.5 M | - | - | $ 7.46 M |  Israel |
 |
Autolus Therapeutics plc
AUTL
|
-284 M | $ 1.46 | 1.04 % | $ 389 M | Britain |
 |
Aptose Biosciences
APTO
|
-22 M | - | -45.71 % | $ 1.2 M | Canada |
 |
AstraZeneca PLC
AZN
|
5.96 B | - | - | $ 96.9 B | Britain |
 |
KalVista Pharmaceuticals
KALV
|
-81.6 M | $ 20.08 | 2.29 % | $ 1.08 B | Britain |
 |
AVROBIO
AVRO
|
-63.2 M | - | 1083.1 % | $ 745 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-8.95 M | $ 2.99 | 2.05 % | $ 4.92 M | Israel |
 |
BioDelivery Sciences International
BDSI
|
41 M | - | -4.8 % | $ 255 M | USA |
 |
Kazia Therapeutics Limited
KZIA
|
-22.8 M | $ 12.42 | 1.26 % | $ 1.65 B |  Australia |
 |
BeiGene, Ltd.
BGNE
|
1.13 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Akero Therapeutics
AKRO
|
-230 M | - | - | $ 3.67 B | USA |